Lexington, Mass.-based Aldeyra Therapeutics reported that the company’s reproxalap hit the mark in the Phase III Tranquility-2 study for dry eye disease. The drug showed statistical superiority for its two primary endpoints.
https://www.pharmalive.com/wp-content/uploads/2022/06/BioSpacedryeye6-8-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-08 12:16:112022-06-08 12:20:10Aldeyra prepares to submit dry eye disease treatment to FDA
